138 related articles for article (PubMed ID: 27215381)
1. Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis.
Grieve S; Gao Y; Hall C; Hu J; Greer PA
Mol Cell Biol; 2016 Aug; 36(15):2078-88. PubMed ID: 27215381
[TBL] [Abstract][Full Text] [Related]
2. Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model.
Nam S; Kim H; Hong D; Park JB; Kim SJ
Anticancer Res; 2017 Nov; 37(11):6291-6302. PubMed ID: 29061812
[TBL] [Abstract][Full Text] [Related]
3. Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells.
Zhang Z; Li HM; Zhou C; Li Q; Ma L; Zhang Z; Sun Y; Wang L; Zhang X; Zhu B; Hong YS; Wu CZ; Liu H
J Exp Clin Cancer Res; 2016 Sep; 35(1):149. PubMed ID: 27658586
[TBL] [Abstract][Full Text] [Related]
4. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
[TBL] [Abstract][Full Text] [Related]
5. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
6. Effect of mesoporous silica nanoparticles co‑loading with 17‑AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2.
Wang C; Zhang R; Tan J; Meng Z; Zhang Y; Li N; Wang H; Chang J; Wang R
Oncol Rep; 2020 May; 43(5):1491-1502. PubMed ID: 32323855
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
[TBL] [Abstract][Full Text] [Related]
8. Comparison of inhibitory effects of 17-AAG nanoparticles and free 17-AAG on HSP90 gene expression in breast cancer.
Ghalhar MG; Akbarzadeh A; Rahmati M; Mellatyar H; Dariushnejad H; Zarghami N; Barkhordari A
Asian Pac J Cancer Prev; 2014; 15(17):7113-8. PubMed ID: 25227799
[TBL] [Abstract][Full Text] [Related]
9. Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer.
Srirangam A; Mitra R; Wang M; Gorski JC; Badve S; Baldridge L; Hamilton J; Kishimoto H; Hawes J; Li L; Orschell CM; Srour EF; Blum JS; Donner D; Sledge GW; Nakshatri H; Potter DA
Clin Cancer Res; 2006 Mar; 12(6):1883-96. PubMed ID: 16551874
[TBL] [Abstract][Full Text] [Related]
10. The combination of Hsp90 inhibitor 17AAG and heavy-ion irradiation provides effective tumor control in human lung cancer cells.
Hirakawa H; Fujisawa H; Masaoka A; Noguchi M; Hirayama R; Takahashi M; Fujimori A; Okayasu R
Cancer Med; 2015 Mar; 4(3):426-36. PubMed ID: 25582113
[TBL] [Abstract][Full Text] [Related]
11. Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer.
Zajac M; Gomez G; Benitez J; Martínez-Delgado B
BMC Med Genomics; 2010 Oct; 3():44. PubMed ID: 20920318
[TBL] [Abstract][Full Text] [Related]
12. 17‑AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA‑MB‑231 breast cancer cells.
Zuo Y; Xu H; Chen Z; Xiong F; Zhang B; Chen K; Jiang H; Luo C; Zhang H
Oncol Rep; 2020 Jun; 43(6):1928-1944. PubMed ID: 32236631
[TBL] [Abstract][Full Text] [Related]
13. Altered molecular pathways decides the treatment outcome of Hsp90 inhibitors against breast cancer cells.
Vykuntham NG; Suran S; Siripini S; John S; Kumar P; Paithankar K; Amere Subbarao S
Toxicol In Vitro; 2020 Jun; 65():104828. PubMed ID: 32184171
[TBL] [Abstract][Full Text] [Related]
14. HSP27 expression levels are associated with the sensitivity of hepatocellular carcinoma cells to 17-allylamino-17-demethoxygeldanamycin.
Cui Y; Wu W; Zhou Y; Xie Q; Liu T; Jin J; Liu K
Future Oncol; 2013 Mar; 9(3):411-8. PubMed ID: 23469976
[TBL] [Abstract][Full Text] [Related]
15. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
Roforth MM; Tan C
Anticancer Drugs; 2008 Aug; 19(7):681-8. PubMed ID: 18594209
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
Sawai A; Chandarlapaty S; Greulich H; Gonen M; Ye Q; Arteaga CL; Sellers W; Rosen N; Solit DB
Cancer Res; 2008 Jan; 68(2):589-96. PubMed ID: 18199556
[TBL] [Abstract][Full Text] [Related]
17. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW
Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065
[TBL] [Abstract][Full Text] [Related]
18. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
[TBL] [Abstract][Full Text] [Related]
19. 17-DMAG induces heat shock protein 90 functional impairment in human bladder cancer cells: knocking down the hallmark traits of malignancy.
Karkoulis PK; Stravopodis DJ; Voutsinas GE
Tumour Biol; 2016 May; 37(5):6861-73. PubMed ID: 26662567
[TBL] [Abstract][Full Text] [Related]
20. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]